Summary of Study ST001017

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000680. The data can be accessed directly via it's Project DOI: 10.21228/M8S684 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001017
Study TitleLarge Scale Profling in Muscle Tissue for Muscle Wasting in Cancer Cachexia (part-XI)
Study SummaryLarge Scale Profiling of muscle wasting in Cancer Cachexia. Muscle samples from 10 control patients, 10 weight stable pancreatic cancer patients, and 10 pancreatic cancer patients with significant weight loss. Samples are divided evenly between males and females.
Mayo Clinic
Last NameGuttridge
First NameDenis
Address520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Submit Date2018-07-15
Analysis Type DetailLC-MS
Release Date2020-07-15
Release Version1
Denis Guttridge Denis Guttridge application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000680
Project DOI:doi: 10.21228/M8S684
Project Title:Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia
Project Summary:Cachexia is a debilitating syndrome that results in severe, involuntary weight loss due to the depletion of skeletal muscle mass. This syndrome occurs in a majority of cancers and contributes to approximately one third of all cancer deaths. Currently, no effective therapy exists to combat this malignant disorder, and disappointing results from recent Phase III clinical trials indicate that a cachexia treatment is not likely to appear soon. Thus, it is clear that greater knowledge of the mechanisms driving muscle wasting in cachexia is needed in order to identify new therapeutic targets and stimulate new clinical trials. Our approach to gaining this knowledge has been to work with muscle biopsies from pancreatic cancer patients, since this population is highly prone to cachexia. We have also been expanding our studies beyond the classical mouse models of cancer cachexia in hopes of finding a new model that better recapitulates the human disease. We recently undertook RNA-Seq analysis comparing muscle biopsies from pancreatic cancer patients with and without cachexia, which has been exciting since this type of analysis has not yet been performed in patient samples. Preliminary results revealed that cachectic muscle was associated with alterations in metabolism. These data provide the rationale for performing metabolomics to ascertain whether specific metabolic pathways or metabolites can be identified as potential drivers of muscle wasting in cachexia or be used as biomarker of cachexia, which the field desperately needs. An additional need is a well-validated animal model of cancer cachexia that accurately reflects the human condition, which can be used to test mechanisms and pre-clinical compounds. We propose to perform these studies under the Mayo Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) Identify metabolic alterations and biomarkers of pancreatic cancer-induced muscle wasting; and 2) Identify a suitable mouse model that recapitulates the metabolic imbalance of muscles from pancreatic cancer cachexia patients. By performing these studies, we will accelerate our understanding of the underlying causes of muscle wasting, which should translate to improving the current pipeline of anticachexia therapies.
Institute:Mayo Clinic
Last Name:Guttridge
First Name:Denis
Address:520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210


Subject ID:SU001056
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Groups Gender
SA063702nhilic-03jun17-012Control Female
SA063703philic-02jun17-005Control Female
SA063704pC18-02jun17-004Control Female
SA063705philic-02jun17-017Control Female
SA063706nC18-03jun17-022_1Control Female
SA063707philic-02jun17-004Control Female
SA063708philic-02jun17-012Control Female
SA063709pC18-02jun17-017Control Female
SA063710nhilic-03jun17-004Control Female
SA063711nhilic-03jun17-005Control Female
SA063712nhilic-03jun17-017Control Female
SA063713nhilic-03jun17-022Control Female
SA063714nC18-03jun17-017_1Control Female
SA063715pC18-02jun17-022Control Female
SA063716pC18-02jun17-012Control Female
SA063717pC18-02jun17-005Control Female
SA063718nC18-03jun17-012_1Control Female
SA063719philic-02jun17-022Control Female
SA063720nC18-03jun17-004_1Control Female
SA063721nC18-03jun17-005_1Control Female
SA063722pC18-02jun17-009Control Male
SA063723philic-02jun17-025Control Male
SA063724pC18-02jun17-006Control Male
SA063725philic-02jun17-006Control Male
SA063726nC18-03jun17-010_1Control Male
SA063727pC18-02jun17-020Control Male
SA063728nC18-03jun17-006_1Control Male
SA063729nhilic-03jun17-020Control Male
SA063730pC18-02jun17-025Control Male
SA063731nhilic-03jun17-025Control Male
SA063732nhilic-03jun17-006Control Male
SA063733nC18-03jun17-009_1Control Male
SA063734pC18-02jun17-010Control Male
SA063735nhilic-03jun17-010Control Male
SA063736nC18-03jun17-020_1Control Male
SA063737philic-02jun17-020Control Male
SA063738nhilic-03jun17-009Control Male
SA063739philic-02jun17-010Control Male
SA063740philic-02jun17-009Control Male
SA063741nC18-03jun17-025_1Control Male
SA063742philic-02jun17-019Weight Losing Female
SA063743philic-02jun17-028Weight Losing Female
SA063744nC18-03jun17-002_1Weight Losing Female
SA063745nC18-03jun17-019_1Weight Losing Female
SA063746nhilic-03jun17-002Weight Losing Female
SA063747nhilic-03jun17-018Weight Losing Female
SA063748nhilic-03jun17-019Weight Losing Female
SA063749philic-02jun17-018Weight Losing Female
SA063750pC18-02jun17-028Weight Losing Female
SA063751pC18-02jun17-018Weight Losing Female
SA063752nC18-03jun17-015_1Weight Losing Female
SA063753philic-02jun17-015Weight Losing Female
SA063754nC18-03jun17-028_1Weight Losing Female
SA063755pC18-02jun17-002Weight Losing Female
SA063756philic-02jun17-002Weight Losing Female
SA063757nC18-03jun17-018_1Weight Losing Female
SA063758nhilic-03jun17-015Weight Losing Female
SA063759pC18-02jun17-019Weight Losing Female
SA063760nhilic-03jun17-028Weight Losing Female
SA063761pC18-02jun17-015Weight Losing Female
SA063762nhilic-03jun17-014Weight Losing Male
SA063763philic-02jun17-001Weight Losing Male
SA063764philic-02jun17-014Weight Losing Male
SA063765philic-02jun17-021Weight Losing Male
SA063766philic-02jun17-024Weight Losing Male
SA063767philic-02jun17-027Weight Losing Male
SA063768nhilic-03jun17-024Weight Losing Male
SA063769nhilic-03jun17-027Weight Losing Male
SA063770nhilic-03jun17-021Weight Losing Male
SA063771nhilic-03jun17-001Weight Losing Male
SA063772nC18-03jun17-014_1Weight Losing Male
SA063773pC18-02jun17-014Weight Losing Male
SA063774pC18-02jun17-024Weight Losing Male
SA063775pC18-02jun17-021Weight Losing Male
SA063776nC18-03jun17-024_1Weight Losing Male
SA063777pC18-02jun17-001Weight Losing Male
SA063778pC18-02jun17-027Weight Losing Male
SA063779nC18-03jun17-001_1Weight Losing Male
SA063780nC18-03jun17-021_1Weight Losing Male
SA063781nC18-03jun17-027_1Weight Losing Male
SA063782philic-02jun17-003Weight Stable Female
SA063783nC18-03jun17-026_1Weight Stable Female
SA063784pC18-02jun17-013Weight Stable Female
SA063785nC18-03jun17-013_1Weight Stable Female
SA063786nC18-03jun17-029_1Weight Stable Female
SA063787pC18-02jun17-003Weight Stable Female
SA063788philic-02jun17-008Weight Stable Female
SA063789philic-02jun17-013Weight Stable Female
SA063790pC18-02jun17-008Weight Stable Female
SA063791nhilic-03jun17-029Weight Stable Female
SA063792nhilic-03jun17-003Weight Stable Female
SA063793philic-02jun17-029Weight Stable Female
SA063794nC18-03jun17-003_1Weight Stable Female
SA063795nhilic-03jun17-008Weight Stable Female
SA063796nhilic-03jun17-013Weight Stable Female
SA063797pC18-02jun17-026Weight Stable Female
SA063798pC18-02jun17-029Weight Stable Female
SA063799nhilic-03jun17-026Weight Stable Female
SA063800philic-02jun17-026Weight Stable Female
SA063801nC18-03jun17-008_1Weight Stable Female
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 120


Collection ID:CO001050
Collection Summary:Tissue and blood donated from Cancer Cachexia Program at Ohio State University
Sample Type:Muscle


Treatment ID:TR001070
Treatment Summary:Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ΒΌ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Sample Preparation:

Sampleprep ID:SP001063
Sampleprep Summary:large scale profiling using muscle tissue

Combined analysis:

Analysis ID AN001659 AN001660 AN001661 AN001662
Analysis type MS MS MS MS
Chromatography type HILIC HILIC Reversed phase Reversed phase
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity
Column Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
MS instrument type QTOF QTOF QTOF QTOF
MS instrument name Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF
Units intensity intensity intensity intensity


Chromatography ID:CH001170
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
Chromatography Type:HILIC
Chromatography ID:CH001171
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
Chromatography Type:Reversed phase


MS ID:MS001534
Analysis ID:AN001659
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001535
Analysis ID:AN001660
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001536
Analysis ID:AN001661
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001537
Analysis ID:AN001662
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF